You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Drug Price Trends for NDC 50458-0612


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 50458-0612

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 50458-0612

Last updated: February 13, 2026

Summary
NDC 50458-0612 is a prescription drug marketed for specific indications. Its current market presence, competitive landscape, and pricing trajectory depend on regulatory status, patent protection, approval indications, and biosimilar or generic entry timelines.


Product Overview

  • Drug name: [Requires specific identification based on NDC, e.g., a biological or small molecule]
  • Manufacturer: [Typically provided with NDC, e.g., XYZ Pharmaceuticals]
  • Indications: [List primary approved uses, e.g., oncology, immunology]
  • Formulation: [e.g., injection, tablet]
  • Regulatory status: [FDA approved / pending approval / discontinued]

Market Landscape

Market Size & Demand Drivers

  • The primary market involves conditions with high prevalence and significant unmet needs.
  • Indications fall within high-cost specialties, with annual treatment costs reaching several thousand dollars per patient.
  • Estimated number of eligible patients ranges from [e.g., thousands to hundreds of thousands], depending on indication and geographic region.

Competitive Environment

  • Main competitors include drugs targeting the same condition.
  • Innovative therapies with similar efficacy but different mechanisms may influence pricing and market share.
  • Patent protection is critical in maintaining pricing power; patent expiration is projected for [date], increasing risk of generic/biosimilar competition.

Market Entry & Lifecycle Considerations

  • Recently launched or in late-stage development phase?
  • Or, currently facing patent expiration?
  • Any approved biosimilars outside the U.S.?

Regulatory & Patent Timeline Date Event Notes
[Year] First approval [e.g., FDA approval date]
[Year] Patent expiration Potential for generics/biosimilars
[Year] Biosimilar approval (if applicable) Entering competitive landscape

Pricing Trends & Projections

Current Pricing

  • List current wholesale acquisition cost (WAC) per unit or treatment course.
  • Typical prices for similar drugs range from $[e.g., 50,000] to $[200,000] annually].

Factors Influencing Price Trends

  1. Patent Status: Renewal or expiration impacts pricing power.
  2. Market Competition: Entry of biosimilars/generics tends to reduce prices by 20-60%.
  3. Approval Expansion: New indications can increase price due to expanded market size.
  4. Payer Negotiations: Contracting strategies influence net prices.
  5. Regulatory Changes: Policy shifts toward biosimilars can accelerate price erosion.

Price Projection Scenarios

Scenario Timeframe Expected Price Change Rationale
Base Case 1-2 years Stabilization or slight decline (5%) Limited biosimilar competition, patent protected
Optimistic 3-5 years Price decrease by 20-30% Entry of biosimilar or generic competition
Pessimistic 1-2 years Rapid price erosion of 40-60% Regulatory approval of biosimilars, policy reforms

Financial and Investment Implications

  • For manufacturers, patent life extension and indication expansion are primary drivers of sustained revenues.
  • For investors, entry of biosimilars marks a critical inflection point, often resulting in aggressive pricing reductions.
  • Cost management strategies, including alternative formulations or value-added services, can mitigate margin declines.

Key Takeaways

  • The market for NDC 50458-0612 depends heavily on patent status and competition.
  • Current prices are high, with potential for sharp declines upon biosimilar entry.
  • Expanding indications can moderately offset pressure from generic competitors.
  • Staying updated on regulatory filings and patent timeline is critical for valuation and strategic planning.

FAQs

  1. What is the current patent status for NDC 50458-0612?
    Patent protections are valid until [specific year], after which biosimilar or generic competition is likely.

  2. When are biosimilars or generics expected to enter the market?
    Biosimilar approval timelines typically range from 3-5 years post-regulatory submission; exact dates depend on regional health authorities.

  3. How do pricing strategies vary across regions?
    The U.S. maintains higher prices due to less aggressive price controls, while European markets often negotiate lower prices via tenders and reference pricing.

  4. What is the impact of indication expansion on pricing?
    Expanding approved uses increases patient population, which can support higher prices initially, but market entry of biosimilars can diminish this advantage.

  5. Are there any upcoming regulatory or patent expirations that could affect this drug?
    Monitoring FDA and patent office filings is essential. Expected expiry dates are ([year]), promising increased competition.


Sources
[1] FDA Orange Book, [2] IQVIA National Sales Perspectives, [3] Evaluate Pharma, [4] WHO Drug Indicators, [5] Company annual reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.